BLAINJECTIONINJECTABLE
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMGALITY (galcanezumab-gnlm) is a monoclonal antibody approved in 2018 for migraine prevention. It binds to calcitonin gene-related peptide (CGRP), a neuropeptide implicated in migraine pathophysiology. Administered via subcutaneous injection, it represents a targeted mechanism for reducing migraine frequency in episodic and chronic migraine patients.
Peak
Product is in peak commercial phase with mature market penetration; team size likely stable with focus on retention and share-of-voice optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Emgality for Migraine in Breastmilk
Started Feb 2024
30 enrolled
Migraine
The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
Started Aug 2020
25 enrolled
Post-Traumatic Headache
Career Relevance
EMGALITY careers are positioned in a mature, peak-stage franchise requiring expertise in managed care navigation, payer relationships, and competitive differentiation within the CGRP class. Roles focus on retention, share growth, and real-world outcomes validation rather than launch momentum.
Brand Manager
Worked on EMGALITY at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.